drugset / Trial / NCT03817411
Telatinib in Combination With Capecitabine/ Oxaliplatin in 1st Line Gastric or GEJ Cancer
Phase 2
Unknown
90 enrolled
Taizhou EOC Pharma Co., Ltd.
Shanghai East Hospital · collabShanghai Zhongshan Hospital · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of the trial is to compare the combination regimen of Telatinib and Capecitabine and Oxaliplatin vs. Capecitabine and Oxaplatin to explore superiority of the Telatinib combination in terms of progression-free survival (PFS) in patients previously untreated for advanced HER2 negative advanced gastric or Gastroesophageal Junction adenocarcinoma.
Timeline
- Start
- 2019-01-25
- Primary completion
- 2020-03-30
- Completion
- 2021-01-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Telatinib | Small molecule | 900 mg | Oral |
| Comparator | Capecitabine | Small molecule | 1000 mg/m2 | Oral |
| Comparator | Oxaliplatin | Small molecule | 130 mg/m2 | Intravenous |